Related Experiment Video
Updated: Apr 28, 2026

Studying Food Reward and Motivation in Humans
Published on: March 19, 2014
Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity
Harry R Chobanian1, Yan Guo1, Ping Liu1
1Departments of Medicinal Chemistry, Metabolic Disorders, Pharmacology, and Drug Metabolism, Merck Research Laboratories , Rahway, New Jersey 07065, United States.
Abstract:
Extensive structure-activity relationship studies of a series derived from atropisomer 1, a previously described chiral benzodiazepine sulfonamide series, led to a potent, brain penetrant and selective compound with excellent preclinical pharmacokinetic across species. We also describe the utilization of a high throughput mouse pharmacodynamic assay which allowed for expedient assessment of pharmacokinetic and brain distribution.
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Obesity
Regulation of Food Intake
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

